About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Cohort A data to be presented in a poster session at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Data reported positive trend in overall survival, including 4 complete responses observed in the certepetide treatment group compared to none in placebo group Data from Cohort B expected in the coming months, with full data from both cohorts to be reported thereafter BASKING RIDGE, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or ...

Company Overview - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [3] - The company is working on its investigational drug candidate, certepetide, which utilizes a novel uptake pathway to enhance the targeting and penetration of anti-cancer drugs in solid tumors [3] Upcoming Event - David J. Mazzo, PhD, President and CEO of Lisata, will present a corporate overview at the Sequire Investor Summit scheduled for January 21-23, 2025, in San Juan, Puerto Rico [1][2] - The presentation is set for January 22 at 10:00 a.m. Atlantic Standard Time [2] Financial and Operational Outlook - Lisata has established significant commercial and R&D partnerships based on its CendR Platform® technology [3] - The company anticipates announcing multiple milestones over the next 1.5 years and projects that its capital will support operations into early 2026, including data milestones from ongoing and planned clinical trials [3]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Award recognizes Lisata’s data-driven approach and innovative therapies designed to address the unmet medical needs of patients with advanced solid tumors Annual BioTech Breakthrough Award is devoted to honoring excellence in life science and biotechnology solutions, services, and companies BASKING RIDGE, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced so ...

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to talk about the latest updates on its clinical trials and its third quarter financial performance. Mazzo highlighted advancements in Lisata's pancreatic cancer program, specifically the ASCEND trial, which is expected to yield important data soon. He noted that the data from this trial’s first cohort would be presented at the upcoming American Society of Clinical Oncology (ASCO) GI Cancers Symposium. Proactive: You're out with your qua ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Financial Performance - For Q3 2024, operating expenses totaled $5.3 million, a decrease of $0.6 million or 10.5% compared to Q3 2023[12] - Net losses for Q3 2024 were $4.9 million, compared to $5.3 million in Q3 2023[14] - Basic and diluted loss per share attributable to common stockholders was $0.59 for Q3 2024, compared to $0.65 for Q3 2023[21] - The net loss for Q3 2024 was $4,930,000, compared to a net loss of $5,261,000 in Q3 2023, reflecting a 6.3% improvement[21] - Investment income for Q3 2024 was $451,000, a decrease from $714,000 in Q3 2023[21] Research and Development - Research and development expenses were approximately $2.5 million, down $0.8 million or 24.8% from $3.4 million in Q3 2023, primarily due to reduced clinical research organization expenses[13] - Research and development expenses for Q3 2024 were $2,542,000, a decrease of 25% from $3,380,000 in Q3 2023[21] - The ASCEND trial is a Phase 2b study evaluating certepetide in combination with SoC chemotherapy for metastatic pancreatic ductal adenocarcinoma, with data from 95 patients expected in January 2025[3] - The BOLSTER trial achieved complete enrollment in first-line cholangiocarcinoma nearly six months ahead of schedule, with topline data anticipated in mid-2025[4] - The CENDIFOX trial is expected to complete enrollment in pancreatic, colon, and appendiceal cancer cohorts by the end of 2024[6] - Lisata has entered into research collaborations to assess certepetide in combination with other therapies for endometriosis and melanoma[11] - Certepetide has received Fast Track designation and Orphan Drug Designation for multiple cancer types, including pancreatic cancer and glioma[3] - The company anticipates a data-rich 2025 with multiple key data readouts projected over the next 18 months[2] Cash and Assets - As of September 30, 2024, cash, cash equivalents, and marketable securities amounted to approximately $35.9 million, expected to fund operations into early 2026[15] - Cash, cash equivalents, and marketable securities decreased to $35,856,000 as of September 30, 2024, from $50,535,000 at the end of 2023[22] - Total assets decreased to $38,199,000 as of September 30, 2024, down from $54,694,000 at the end of 2023[22] - Total liabilities decreased to $4,763,000 as of September 30, 2024, from $6,800,000 at the end of 2023[22] - Total equity decreased to $33,436,000 as of September 30, 2024, down from $47,894,000 at the end of 2023[22] Operating Expenses - General and administrative expenses increased to $2,794,000 in Q3 2024 from $2,584,000 in Q3 2023, representing an 8% increase[21] - Total operating expenses for Q3 2024 were $5,336,000, down 10.5% from $5,964,000 in Q3 2023[21]